Joseph Ventura1, Kenneth L Subotnik2, Denise Gretchen-Doorly2, Laurie Casaus2, Michael Boucher2, Alice Medalia3, Morris D Bell4, Gerhard S Hellemann2, Keith H Nuechterlein5. 1. Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, United States. Electronic address: jventura@mednet.ucla.edu. 2. Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, United States. 3. Department of Psychiatry, Columbia University Medical Center, New York, New York. 4. Department of Psychiatry, Yale University, New Haven, Connecticut. 5. Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, United States; Department of Psychology, University of California, Los Angeles, United States.
Abstract
BACKGROUND: Meta-analyses have reported that the effects of cognitive remediation might go beyond improvement in cognition to include unexpected benefits for schizophrenia patients such as negative symptom reduction and improvements in functioning. In addition, some evidence indicated that these potentially beneficial effects are also present in the initial course of schizophrenia, but work in this area is still developing. METHOD: A RCT compared Cognitive Remediation (CR) to Healthy Behaviors Training (HBT) in 80 patients (78% male) with a mean age of 21.9years and mean education of 12.3years who had a first psychotic episode within two years of study entry. Participants were trained using CR programs or received HBT involving 50 sessions over 6months and then booster sessions over the next 6months. The SANS and BPRS were used to assess symptoms. The UCLA Social Attainment Survey assessed social functioning. RESULTS: Using GLMM, improvements over 12months were found favoring CR for SANS Expressive Symptoms (p<0.01), which was composed of Affective Flattening (p<0.01) and Alogia (p=0.04), and for SANS Experiential Symptoms, composed of Avolition/Apathy (p=0.04) and Anhedonia/Asociality (p<0.01). CR was associated with improvements in social functioning (p=0.05) as compared to HBT. CONCLUSIONS: We confirmed that the beneficial effects of CR appear to extend beyond cognition to improvements in negative symptoms and social functioning in early course schizophrenia patients. These results suggest that cognitive remediation might have an impact when the reduction of risk factors for chronicity is most critical for promoting recovery.
BACKGROUND: Meta-analyses have reported that the effects of cognitive remediation might go beyond improvement in cognition to include unexpected benefits for schizophrenia patients such as negative symptom reduction and improvements in functioning. In addition, some evidence indicated that these potentially beneficial effects are also present in the initial course of schizophrenia, but work in this area is still developing. METHOD: A RCT compared Cognitive Remediation (CR) to Healthy Behaviors Training (HBT) in 80 patients (78% male) with a mean age of 21.9years and mean education of 12.3years who had a first psychotic episode within two years of study entry. Participants were trained using CR programs or received HBT involving 50 sessions over 6months and then booster sessions over the next 6months. The SANS and BPRS were used to assess symptoms. The UCLA Social Attainment Survey assessed social functioning. RESULTS: Using GLMM, improvements over 12months were found favoring CR for SANS Expressive Symptoms (p<0.01), which was composed of Affective Flattening (p<0.01) and Alogia (p=0.04), and for SANS Experiential Symptoms, composed of Avolition/Apathy (p=0.04) and Anhedonia/Asociality (p<0.01). CR was associated with improvements in social functioning (p=0.05) as compared to HBT. CONCLUSIONS: We confirmed that the beneficial effects of CR appear to extend beyond cognition to improvements in negative symptoms and social functioning in early course schizophrenia patients. These results suggest that cognitive remediation might have an impact when the reduction of risk factors for chronicity is most critical for promoting recovery.
Authors: J M Kane; E Aguglia; A C Altamura; J L Ayuso Gutierrez; N Brunello; W W Fleischhacker; W Gaebel; J Gerlach; J D Guelfi; W Kissling; Y D Lapierre; E Lindström; J Mendlewicz; G Racagni; L S Carulla; N R Schooler Journal: Eur Neuropsychopharmacol Date: 1998-02 Impact factor: 4.600
Authors: Keith H Nuechterlein; Joseph Ventura; Sarah C McEwen; Denise Gretchen-Doorly; Sophia Vinogradov; Kenneth L Subotnik Journal: Schizophr Bull Date: 2016-07 Impact factor: 9.306
Authors: Joseph Ventura; Gerhard S Hellemann; April D Thames; Vanessa Koellner; Keith H Nuechterlein Journal: Schizophr Res Date: 2009-07-22 Impact factor: 4.939
Authors: Zanjbeel Mahmood; Amber V Keller; Cynthia Z Burton; Lea Vella; Georg E Matt; Susan R McGurk; Elizabeth W Twamley Journal: Psychiatr Serv Date: 2019-06-12 Impact factor: 3.084
Authors: S Galderisi; A Mucci; S Dollfus; M Nordentoft; P Falkai; S Kaiser; G M Giordano; A Vandevelde; M Ø Nielsen; L B Glenthøj; M Sabé; P Pezzella; I Bitter; W Gaebel Journal: Eur Psychiatry Date: 2021-02-18 Impact factor: 5.361
Authors: Maura Malpetti; P Simon Jones; Kamen A Tsvetanov; Timothy Rittman; John C van Swieten; Barbara Borroni; Raquel Sanchez-Valle; Fermin Moreno; Robert Laforce; Caroline Graff; Matthis Synofzik; Daniela Galimberti; Mario Masellis; Maria Carmela Tartaglia; Elizabeth Finger; Rik Vandenberghe; Alexandre de Mendonça; Fabrizio Tagliavini; Isabel Santana; Simon Ducharme; Chris R Butler; Alexander Gerhard; Johannes Levin; Adrian Danek; Markus Otto; Giovanni B Frisoni; Roberta Ghidoni; Sandro Sorbi; Carolin Heller; Emily G Todd; Martina Bocchetta; David M Cash; Rhian S Convery; Georgia Peakman; Katrina M Moore; Jonathan D Rohrer; Rogier A Kievit; James B Rowe Journal: Alzheimers Dement Date: 2020-12-14 Impact factor: 16.655
Authors: Francesc Estrada; Josep Maria Crosas; Maribel Ahuir; Sara Pérez-Muñoz; Wanda Zabala; Raquel Aguayo; Juan David Barbero; Itziar Montalvo; Meritxell Tost; Laura Llauradó; Armand Guardia; Diego Palao; José Antonio Monreal; Javier Labad Journal: Front Psychiatry Date: 2020-07-07 Impact factor: 4.157
Authors: Mohanbabu Rathnaiah; Elizabeth B Liddle; Lauren Gascoyne; Jyothika Kumar; Mohammad Zia Ul Haq Katshu; Catherine Faruqi; Christina Kelly; Malkeet Gill; Sian Robson; Matt Brookes; Lena Palaniyappan; Peter Morris; Peter F Liddle Journal: Schizophr Bull Open Date: 2020-06-25